The Technical Analyst
Acurx Pharmaceuticals, [ACXP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Acurx Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.49% $2.02
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 31.83 mill |
| EPS: | -1.150 |
| P/E: | -1.760 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 15.76 mill |
| Avg Daily Volume: | 0.101 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.760 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.30x |
| Company: PE -1.760 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.590 (-70.80%) $-1.430 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.808 - 2.23 ( +/- 10.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-23 | Luci David P | Buy | 250 000 | Stock Option |
| 2024-02-23 | Shawah Robert G. | Buy | 145 000 | Stock Option |
| 2024-02-23 | Deluccia Robert J | Buy | 250 000 | Stock Option |
| 2024-01-19 | Sailer Carl | Buy | 19 737 | Common Stock |
| 2024-01-19 | Sailer Carl | Sell | 19 737 | Warrants for Common Stock |
| INSIDER POWER |
|---|
| 76.78 |
| Last 61 transactions |
| Buy: 3 435 791 | Sell: 229 212 |
Forecast:
16:00 - $2.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.00
Forecast 2: 16:00 - $2.00
Forecast 3: 16:00 - $2.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.02 (-0.49% ) |
| Volume | 0.0851 mill |
| Avg. Vol. | 0.101 mill |
| % of Avg. Vol | 84.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACXP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Latest Press Releases
2024-04-25 10:12:00 - Press Release
Acurx Pharmaceuticals Announces Presentation Of Ibezapolostat Phase 2 Clinical Trial Results At Upcoming Escmid 2024 Scientific Conference
Staten island, n.y., april 25, 2024 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat phase 2 clinical trial in patients with c.
2024-03-21 07:01:00 - Press Release
Acurx Pharmaceuticals, Inc. Announces Participation In The Ld Micro Invitational Xiv
Staten island, new york--(newsfile corp. - march 21, 2024) - acurx pharmaceuticals, inc. (nasdaq: acxp) announced today that it will be presenting at the 14th annual ld micro invitational at the sofitel new york on april 8th-9th, 2024. the event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
2024-03-18 07:01:00 - Press Release
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2023 Results And Provides Business Update
Staten island, n.y. , march 18, 2024 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("we" or "acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended december 31, 2023.
2024-03-04 07:01:00 - Press Release
Acurx Pharmaceuticals, Inc. To Discuss Fourth Quarter And Full Year 2023 Financial Results On March 18, 2024 Conference Call And Provide Business Update
Staten island, n.y. , march 4, 2024 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the company will release its fourth quarter and full year 2023 financial results on monday, march 18, 2024, at 8:00 am et before the u.s. financial markets open.
2024-02-27 07:01:00 - Press Release
Acurx Announces Fda Has Granted An End Of Phase 2 Meeting For Ibezapolstat For C. Difficile Infection And The European Medicines Agency Granted Sme Designation For Ibezapolstat Eu Development
As previously announced, planning is underway with fda to advance ibezapolstat into international phase 3 clinical trials for treatment of c. difficile infection (cdi) as anticipated, an end of phase 2 meeting (eop2) with fda is now confirmed to occur in late april 2024 to finalize the phase 3 development plan per fda guidance, acurx also announced it has submitted the required pre-meeting briefing document to fda yesterday, february 26, 2024 sme (small and medium-sized enterprise) designation has been granted by the ema (european medicines agency) which allows acurx to benefit from fee incentives and other support from the ema for eu marketing authorization ibezapolstat has previously received fda qidp and fast-track designation staten island, n...
Latest News
2024-03-18 11:19:09 - Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
2024-03-04 07:01:00 - PRNewsWire
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.
2024-01-23 07:01:00 - PRNewsWire
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
STATEN ISLAND, N.Y. , Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P.
2024-01-22 12:04:50 - Seeking Alpha
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expectations regarding the release of sustained clinical cure rates. Acurx is expected to release additional data, including 94-day sustained clinical cure rates, which could further establish its antibiotic as a preferred treatment for C. diff.
2023-08-22 07:01:00 - PRNewsWire
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P.
2023-06-20 07:01:00 - PRNewsWire
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. STATEN ISLAND, N.Y.
2023-03-16 14:20:36 - Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Robert Shawah - Co-Founder & Chief Financial Officer David Luci - President & Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim James Molloy - Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceutical Fourth Quarter and Full Year 2022 Financial Results and Business Update. [Operator Instructions] As a reminder, this conference is being recorded.
2023-01-16 08:01:00 - PRNewsWire
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND, N.Y. , Jan. 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023.
2022-11-14 11:14:09 - Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 8:49 AM ET Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Operator Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022.
2022-11-01 08:01:00 - PRNewsWire
Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 third quarter financial results on Monday, November 14, 2022, at 8:30 am ET before the U.S. financial markets open.